Safety and Efficacy of Bojungikki-Tang in Advanced NSCLC Patients Receiving Treatment with Immune Checkpoint Inhibitors: Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Trial

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) is a major treatment option for several types of cancer, including non-small cell lung cancer (NSCLC). The proposed study aims to investigate the safety and efficacy of Bojungikki-tang (BJIKT) therapy (an herbal medicine) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Mi Mi, Jeong, Mi-Kyung, Choi, Chang Min, Lee, Seung Hyeun, Chun, Jaemoo, Yi, Jin-Mu, Jang, Ho, Lee, Sung Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002386/
https://www.ncbi.nlm.nih.gov/pubmed/36901517
http://dx.doi.org/10.3390/ijerph20054507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002386/
https://www.ncbi.nlm.nih.gov/pubmed/36901517
http://dx.doi.org/10.3390/ijerph20054507

Ejemplares similares